Virios Therapeutics (NASDAQ:VIRI – Get Free Report) had its price objective boosted by stock analysts at HC Wainwright from $0.20 to $5.00 in a report issued on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the stock.
Separately, Maxim Group started coverage on shares of Virios Therapeutics in a research report on Thursday, June 20th. They set a “buy” rating and a $1.00 target price on the stock.
Get Our Latest Stock Analysis on VIRI
Virios Therapeutics Stock Up 12.4 %
Virios Therapeutics (NASDAQ:VIRI – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. During the same quarter last year, the company earned ($0.08) earnings per share. On average, research analysts expect that Virios Therapeutics will post -0.22 earnings per share for the current fiscal year.
About Virios Therapeutics
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
See Also
- Five stocks we like better than Virios Therapeutics
- Earnings Per Share Calculator: How to Calculate EPS
- 3 Momentum Trades for October With Ample Upside Ahead
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.